Tuesday, March 16, 2010 11:24:11 AM
JIm Cramer Mad money Fund Long Term Pick http://madmoneyfund.blogspot.com/201...-for-2010.html
ProtoKinetix, Inc.(PKTX) .10 a share Target price .20
ProtoKinetix, Inc. is a research and product development stage company. The Company owns the world-wide rights to a family of anti-aging glycoproteins, trademarked as AAGPs. In scientific tests AAGPs have demonstrated the ability to improve the health and extend the life of biologically sensitive cells, which have been subjected to severe stress conditions under laboratory controlled test conditions. AAGPs are stable and non-toxic. As of December 31, 2008, the Company had not sold any products. The Company is also researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (AFGP). - Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP(TM) in the freeze-thaw process. One future approach to increasing diabetics' insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient's stem cells. This is where AAGP(TM) can make a very beneficial contribution.
The Edmonton Protocol has successfully transplanted islet cells from donated pancreases into the liver and subsequently produced insulin in the patients. This protocol has been adopted by hospitals around the world, however, the lack of donors and the requirement for anti-rejection drugs severely restricts its use on a wide spread basis. The scientific community has been aggressively pursuing the ability to differentiate a person's stem cells into islet cells. This achievement will provide a compatible source of islet cells that can be used in conjunction with the Edmonton Protocol. In order for this exciting new treatment to be both successful and economic on a universal scale, it is imperative that a very high recovery rate of islet cells is achieved. ProtoKinetix has demonstrated that it will be playing a pivotal role in the future treatment of diabetes.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP(TM)) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue.this is a long & risky term play ! PKTX ,Shows Promise as a Tool in Diabetes Treatment / Cure.
Recent PKTX News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/17/2024 07:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 07:13:41 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 05/15/2024 09:14:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 12:46:59 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM